Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Mongodb Inc (MDB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Mongodb Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Mongodb Inc trades at $344 (market cap $27.51B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Mongodb Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | MDB | |
|---|---|---|
Market Cap | $39.89B | $27.51B |
Sector | Health | Technology |
52-Week High | $491.22 | $440.25 |
52-Week Low | $278.09 | $201.08 |
Enterprise Value | $38.15B | $25.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
MongoDB (MDB) trades at $342.08, down 5.73% in the latest session, amid mixed technical signals with a bullish moving average trend but overbought RSI readings. The company shows strong revenue growth, reaching $2.01B in 2025, with consistent earnings beats in recent quarters, though it remains unprofitable with a net margin of -1.12%. Recent news highlights AI-driven demand boosting database sales and raised FY2027 revenue guidance to $2.92–$2.96B.
Outlook remains positive with 82% analyst buy ratings and a $400.39 consensus target, offering ~17% upside. Key risks include ongoing profitability challenges, competitive pressures, and legal scrutiny over fiduciary duties. Revenue growth and AI adoption present opportunities, but investors should monitor margin improvement and execution against guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →
